Regeneron Pharmaceuticals (REGN) Non-Current Debt (2014 - 2026)

Regeneron Pharmaceuticals' Non-Current Debt history runs 9 years deep, the most recent figure standing at $2.0 billion for Q1 2026.

• On a quarterly basis, Non-Current Debt changed 0.07% year-over-year to $2.0 billion in Q1 2026; TTM through Mar 2026 was $2.0 billion, a 0.07% change from a year earlier, with the FY2025 full-year figure at $2.0 billion, changed 0.08% from the prior year.
• Non-Current Debt was little changed at $2.0 billion in Q1 2026 per REGN's latest filing, from $2.0 billion in the prior quarter.
• Across five years, Non-Current Debt topped out at $2.0 billion in Q1 2026 and bottomed at $2.0 billion in Q1 2022.
• The 5-year median for Non-Current Debt is $2.0 billion (2024), against an average of $2.0 billion.
• Across the five-year window, Non-Current Debt rose 0.08% in 2022 and grew 0.07% in 2026, its largest moves.
• Year by year, Non-Current Debt stood at $2.0 billion in 2022, then rose by 0.08% to $2.0 billion in 2023, then grew by 0.08% to $2.0 billion in 2024, then advanced by 0.08% to $2.0 billion in 2025, then rose by 0.02% to $2.0 billion in 2026.
• Per Business Quant, the three latest REGN Non-Current Debt figures stand at $2.0 billion (Q1 2026), $2.0 billion (Q4 2025), and $2.0 billion (Q3 2025).